Deloitte Advises Sina Drug in PharMerica Investment
Deloitte Corporate Finance acted as the exclusive financial advisor to Sina Drug Corporation (d/b/a Onco360) in its investment from PharMerica Corporation.
As the largest independent provider of oncology pharmacy services in the United States, Onco360 will serve as a key strategic addition to PharMerica’s pharmacy and care management platform.
“Onco360 has built a reputation as a specialty oncology pharmacy and clinical support services organization, and we were pleased to have advised them in this transaction,” said Dave Vorhoff, managing director, DCF, and co-head of DCF’s life sciences and healthcare group.
Onco360 is an independent provider of oncology pharmacy services.
PharMerica Corporation is an institutional pharmacy, specialty infusion and hospital pharmacy management services company servicing healthcare facilities.